Dietmar Siemann

Summary

Affiliation: University of Florida
Country: USA

Publications

  1. ncbi request reprint Targeting the tumor vasculature: a strategy to improve radiation therapy
    Dietmar W Siemann
    Department of Radiation Oncology, Shands Cancer Center, University of Florida, 2000 SW Archer Road, Gainesville, FL 32610, USA
    Expert Rev Anticancer Ther 4:321-7. 2004
  2. pmc Vascular targeted therapies in oncology
    Dietmar W Siemann
    Department of Radiation Oncology, University of Florida, 2000 SW Archer Road, Gainesville, FL, USA
    Cell Tissue Res 335:241-8. 2009
  3. pmc Constitutively active c-Met kinase in PC-3 cells is autocrine-independent and can be blocked by the Met kinase inhibitor BMS-777607
    Yao Dai
    Department of Radiation Oncology, University of Florida, 2033 Mowry Road, Cancer Genetic Research Complex, Room 485E, Gainesville, FL 32610, USA
    BMC Cancer 12:198. 2012
  4. doi request reprint An update on the clinical development of drugs to disable tumor vasculature
    Dietmar W Siemann
    Professor and Associate Chair for Research, University of Florida, Department of Radiation Oncology, Shands Cancer Center, 2000 SW Archer Road, Gainesville, FL 32610, USA 1 352 265 0287 1 352 265 0759
    Expert Opin Drug Discov 2:1357-67. 2007
  5. pmc Src-signaling interference impairs the dissemination of blood-borne tumor cells
    Dietmar W Siemann
    Department of Radiation Oncology and Shands Cancer Center, University of Florida, 2000 SW Archer Road, Gainesville, FL 32610, USA
    Cell Tissue Res 349:541-50. 2012
  6. ncbi request reprint Therapeutic strategies that selectively target and disrupt established tumor vasculature
    Dietmar W Siemann
    Department of Radiation Oncology, Shands Cancer Center, 2000 SW Archer Road, Gainesville, FL 32610, USA
    Hematol Oncol Clin North Am 18:1023-37, viii. 2004
  7. ncbi request reprint Efficacy of combined antiangiogenic and vascular disrupting agents in treatment of solid tumors
    Dietmar W Siemann
    Department of Radiation Oncology, Shands Cancer Center, University of Florida, Gainesville, FL, USA
    Int J Radiat Oncol Biol Phys 60:1233-40. 2004
  8. ncbi request reprint Differentiation and definition of vascular-targeted therapies
    Dietmar W Siemann
    Department of Radiation Oncology, University of Florida, PO Box 100385, Gainesville, FL 32610, USA
    Clin Cancer Res 11:416-20. 2005
  9. ncbi request reprint The vascular disrupting agent ZD6126 shows increased antitumor efficacy and enhanced radiation response in large, advanced tumors
    Dietmar W Siemann
    Department of Radiation Oncology, University of Florida Shands Cancer Center, Gainesville, FL 32610, USA
    Int J Radiat Oncol Biol Phys 62:846-53. 2005
  10. pmc A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P)
    Dietmar W Siemann
    Department of Radiation Oncology, University of Florida, 2000 SW Archer Road, Gainesville, FL 32610, USA
    Expert Opin Investig Drugs 18:189-97. 2009

Research Grants

Collaborators

Detail Information

Publications53

  1. ncbi request reprint Targeting the tumor vasculature: a strategy to improve radiation therapy
    Dietmar W Siemann
    Department of Radiation Oncology, Shands Cancer Center, University of Florida, 2000 SW Archer Road, Gainesville, FL 32610, USA
    Expert Rev Anticancer Ther 4:321-7. 2004
    ..Indeed, the application of such strategies as adjuvants to conventional radiation treatments offers unique opportunities to develop more effective cancer therapies...
  2. pmc Vascular targeted therapies in oncology
    Dietmar W Siemann
    Department of Radiation Oncology, University of Florida, 2000 SW Archer Road, Gainesville, FL, USA
    Cell Tissue Res 335:241-8. 2009
    ....
  3. pmc Constitutively active c-Met kinase in PC-3 cells is autocrine-independent and can be blocked by the Met kinase inhibitor BMS-777607
    Yao Dai
    Department of Radiation Oncology, University of Florida, 2033 Mowry Road, Cancer Genetic Research Complex, Room 485E, Gainesville, FL 32610, USA
    BMC Cancer 12:198. 2012
    ..In the current study we examined the response of PC-3 cells to an anti-HGF neutralizing antibody or a small molecule Met kinase inhibitor (BMS-777607)...
  4. doi request reprint An update on the clinical development of drugs to disable tumor vasculature
    Dietmar W Siemann
    Professor and Associate Chair for Research, University of Florida, Department of Radiation Oncology, Shands Cancer Center, 2000 SW Archer Road, Gainesville, FL 32610, USA 1 352 265 0287 1 352 265 0759
    Expert Opin Drug Discov 2:1357-67. 2007
    ..In the following paper the authors review vascular disrupting therapies...
  5. pmc Src-signaling interference impairs the dissemination of blood-borne tumor cells
    Dietmar W Siemann
    Department of Radiation Oncology and Shands Cancer Center, University of Florida, 2000 SW Archer Road, Gainesville, FL 32610, USA
    Cell Tissue Res 349:541-50. 2012
    ..The results demonstrate that Src inhibition most effectively interferes with the establishment of secondary tumor deposits when treatments are administered while tumor cells are in the initial phases of dissemination...
  6. ncbi request reprint Therapeutic strategies that selectively target and disrupt established tumor vasculature
    Dietmar W Siemann
    Department of Radiation Oncology, Shands Cancer Center, 2000 SW Archer Road, Gainesville, FL 32610, USA
    Hematol Oncol Clin North Am 18:1023-37, viii. 2004
    ..This articles discusses therapeutic strategies that selectively target and disrupt established tumor vasculature...
  7. ncbi request reprint Efficacy of combined antiangiogenic and vascular disrupting agents in treatment of solid tumors
    Dietmar W Siemann
    Department of Radiation Oncology, Shands Cancer Center, University of Florida, Gainesville, FL, USA
    Int J Radiat Oncol Biol Phys 60:1233-40. 2004
    ....
  8. ncbi request reprint Differentiation and definition of vascular-targeted therapies
    Dietmar W Siemann
    Department of Radiation Oncology, University of Florida, PO Box 100385, Gainesville, FL 32610, USA
    Clin Cancer Res 11:416-20. 2005
    ....
  9. ncbi request reprint The vascular disrupting agent ZD6126 shows increased antitumor efficacy and enhanced radiation response in large, advanced tumors
    Dietmar W Siemann
    Department of Radiation Oncology, University of Florida Shands Cancer Center, Gainesville, FL 32610, USA
    Int J Radiat Oncol Biol Phys 62:846-53. 2005
    ..The efficacy of ZD6126 was investigated in large vs. small tumors in a variety of animal models...
  10. pmc A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P)
    Dietmar W Siemann
    Department of Radiation Oncology, University of Florida, 2000 SW Archer Road, Gainesville, FL 32610, USA
    Expert Opin Investig Drugs 18:189-97. 2009
    ..Finally, the potential of combining VDAs with antiangiogenic therapies has shown considerable promise in preclinical models and such combinations are now beginning to be evaluated in patients...
  11. pmc Dual targeting of tumor vasculature: combining Avastin and vascular disrupting agents (CA4P or OXi4503)
    Dietmar W Siemann
    Department of Radiation Oncology, University of Florida College of Medicine, Gainesville, FL 32610, USA
    Anticancer Res 28:2027-31. 2008
    ..This study evaluated the therapeutic efficacy of combining vascular disrupting agents with antiangiogenic agents...
  12. pmc The vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor cediranib (Recentin; AZD2171) inhibits endothelial cell function and growth of human renal tumor xenografts
    Dietmar W Siemann
    Department of Radiation Oncology, University of Florida, Gainesville, FL 32610, USA
    Int J Radiat Oncol Biol Phys 73:897-903. 2009
    ..The goal of this study was to examine the therapeutic potential of the vascular endothelial growth factor (VEGF) signaling inhibitor cediranib in a human model of renal cell carcinoma (Caki-1)...
  13. pmc Impact of tumor cell VEGF expression on the in vivo efficacy of vandetanib (ZACTIMA; ZD6474)
    Dietmar W Siemann
    Department of Radiation Oncology, University of Florida, Gainesville, Florida 32610, U S A
    Anticancer Res 29:1987-92. 2009
    ..VEGF is the key player in tumor angiogenesis. In the current study, the impact of VEGF expression on the response of tumors to the VEGFR2 associated tyrosine kinase inhibitor vandetanib was evaluated...
  14. pmc The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents
    Dietmar W Siemann
    Department of Radiation Oncology, University of Florida College of Medicine, Gainesville, FL, USA
    Cancer Treat Rev 37:63-74. 2011
    ..Preclinical studies with the different Tumor-VDA classes have demonstrated key tumor-selective anti-vascular and anti-tumor effects...
  15. ncbi request reprint Vascular-targeting therapies for treatment of malignant disease
    Dietmar W Siemann
    Department of Radiation Oncology, University of Florida, Gainesville, Florida 32610, USA
    Cancer 100:2491-9. 2004
    ....
  16. ncbi request reprint Enhancement of radiation therapy by vascular targeting agents
    Dietmar W Siemann
    Department of Radiation Oncology, University of Florida Shands Cancer Center, 2000 SW Archer Road, Gainesville, FL 32610, USA
    Curr Opin Investig Drugs 3:1660-5. 2002
    ..The application of such vascular targeting strategies as adjuvants to conventional therapeutics such as radiotherapy, offers unique opportunities to develop even more effective cancer therapies...
  17. ncbi request reprint Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy
    Dietmar W Siemann
    Department of Radiation Oncology, Shands Cancer Center, University of Florida, Gainesville, FL 32610, USA
    Int J Cancer 99:1-6. 2002
    ..In addition, the inclusion of the antivascular agents did not increase bone marrow stem cell toxicity associated with these anticancer drugs, thus giving rise to a therapeutic gain...
  18. ncbi request reprint Enhancement of radiation therapy by the novel vascular targeting agent ZD6126
    Dietmar W Siemann
    Department of Radiation Oncology, Shands Cancer Center, University of Florida, 2000 SW Archer Road, Box 100385, Gainesville, FL 32610, USA
    Int J Radiat Oncol Biol Phys 53:164-71. 2002
    ....
  19. ncbi request reprint Antitumor efficacy of conventional anticancer drugs is enhanced by the vascular targeting agent ZD6126
    Dietmar W Siemann
    Department of Radiation Oncology, Shands Cancer Center, University of Florida, Gainesville, FL 32606, USA
    Int J Radiat Oncol Biol Phys 54:1512-7. 2002
    ....
  20. ncbi request reprint Targeting the tumor vasculature: enhancing antitumor efficacy through combination treatment with ZD6126 and ZD6474
    Wenyin Shi
    Department of Radiation Oncology, Shands Cancer Center, University of Florida, Gainesville, FL 32610, USA
    In Vivo 19:1045-50. 2005
    ..The antitumor efficacy of combination therapy of the vascular disrupting agent ZD6126 and antiangiogenic agent ZD6474 was evaluated in the models of human colorectal (HT29) and ovarian carcinoma (OW1)...
  21. pmc Leukemia regression by vascular disruption and antiangiogenic therapy
    Gerard J Madlambayan
    Department of Medicine, University of Florida, Gainesville, USA
    Blood 116:1539-47. 2010
    ..Together, these data show that OXi4503 alone is capable of regressing AML by a multitargeted mechanism and that the addition of bevacizumab mitigates reactive angiogenesis...
  22. ncbi request reprint Current development status of small-molecule vascular disrupting agents
    David J Chaplin
    OXiGENE Inc, 230 Third Avenue, Waltham, MA 02451, USA
    Curr Opin Investig Drugs 7:522-8. 2006
    ..This review discusses the small-molecule VDAs in clinical development. In addition, the potential for combination therapy with VDAs and traditional anticancer therapies, such as radiation, chemotherapy and anti-angiogenics is described...
  23. ncbi request reprint Preclinical evaluations of therapies combining the vascular targeting agent combretastatin A-4 disodium phosphate and conventional anticancer therapies in the treatment of Kaposi's sarcoma
    Lingyun Li
    Department of Pharmacology and Experimental Therapeutics, Shands Cancer Center, University of Florida, Gainesville 32610, USA
    Acta Oncol 41:91-7. 2002
    ..Such repeated CA4DP exposures also significantly increased the response of KS xenografts to cisplatin. These findings suggest that CA4DP ought to be considered as a candidate agent for therapeutic evaluation in AIDS-KS patients...
  24. ncbi request reprint Evaluations of vascular disrupting agents CA4P and OXi4503 in renal cell carcinoma (Caki-1) using a silicon based microvascular casting technique
    Howard W Salmon
    Department of Radiation Oncology, Shands Cancer Center at the University of Florida, Gainesville, FL, USA
    Eur J Cancer 42:3073-8. 2006
    ....
  25. ncbi request reprint Impact of VEGF expression on the physiological characteristics of clonal cell lines
    Christina M Norris
    Department of Radiation Oncology, Shands Cancer Center, University of Florida, Gainesville, Florida 32610, USA
    In Vivo 20:815-21. 2006
    ..Vascular endothelial growth factor (VEGF) plays a crucial role in tumor angiogenesis and growth in most solid neoplasia...
  26. ncbi request reprint VEGF-associated tyrosine kinase inhibition increases the tumor response to single and fractionated dose radiotherapy
    William D Brazelle
    Department of Radiation Oncology, Shands Cancer Center, University of Florida, Gainesville, FL, USA
    Int J Radiat Oncol Biol Phys 65:836-41. 2006
    ....
  27. ncbi request reprint Preclinical studies of the novel vascular disrupting agent MN-029
    Wenyin Shi
    Department of Radiation Oncology, Shands Cancer Center, University of Florida, Gainesville, FL 32610, USA
    Anticancer Res 25:3899-904. 2005
    ..Vascular disrupting agents (VDAs) are designed to cause a rapid and selective shutdown of the established tumor vasculature, which leads to secondary ischemic tumor cell death...
  28. ncbi request reprint Activity of the vascular targeting agent combretastatin A-4 disodium phosphate in a xenograft model of AIDS-associated Kaposi's sarcoma
    Amyn M Rojiani
    Department of Interdisciplinary Oncology, H Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, USA
    Acta Oncol 41:98-105. 2002
    ..These findings demonstrate not only the marked susceptibility of the KS model to CA4DP but also its potential application in studies related to the pathogenesis and therapy of AIDS-KS...
  29. pmc In vivo functional differences in microvascular response of 4T1 and Caki-1 tumors after treatment with OXi4503
    Mamta Wankhede
    J Crayton Pruitt Family Department of Biomedical Engineering, University of Florida, Gainesville, FL 32611, USA
    Oncol Rep 23:685-92. 2010
    ..The differential responses of these two tumor-types suggest that further investigation of the mechanisms of action of VDAs and individual characterization of tumor VDA-responses may be needed for optimal clinical use of these agents...
  30. ncbi request reprint Gene therapy delivery of endostatin enhances the treatment efficacy of radiation
    Wenyin Shi
    Department of Pharmacology and Experimental Therapeutics, University of Florida, Gainesville, FL 32610, USA
    Radiother Oncol 66:1-9. 2003
    ..To evaluate whether sustained expression of mouse endostatin by adeno-associated virus (AAV)-mediated gene transfer can enhance the treatment efficacy of ionizing radiation...
  31. pmc Characterizing the tumor response to treatment with combretastatin A4 phosphate
    Beth A Salmon
    Department of Pharmacology and Therapeutics, Shands Cancer Center, University of Florida, Gainesville, FL 32610, USA
    Int J Radiat Oncol Biol Phys 68:211-7. 2007
    ..To examine the pathophysiologic impact of treatment with combretastatin A4 phosphate (CA4P) in regions of tumors that ultimately either necrose or survive treatment with this agent...
  32. ncbi request reprint Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies
    Michael R Horsman
    Department of Experimental Clinical Oncology, Aarhus University Hospital, Aarhus, Denmark
    Cancer Res 66:11520-39. 2006
    ..This review aims to discuss the pathophysiologic changes induced by VTAs and the implications of these effects on the potential use of VTAs in combined modality therapy...
  33. ncbi request reprint Adeno-associated virus-mediated gene transfer of endostatin inhibits angiogenesis and tumor growth in vivo
    Wenyin Shi
    Department of Pharmacology and Experimental Therapeutics, University of Florida, Gainesville, Florida 32610, USA
    Cancer Gene Ther 9:513-21. 2002
    ..This endostatin level was sufficient to inhibit tumor cell-induced angiogenesis and to suppress both the initiation and subsequent growth of a human colorectal cancer model...
  34. pmc Support of a free radical mechanism for enhanced antitumor efficacy of the microtubule disruptor OXi4503
    Lori Rice
    Department of Radiation Oncology, University of Florida, Gainesville, FL 32610, USA
    Microvasc Res 81:44-51. 2011
    ..These findings indicate that while the predominant in vivo effect of OXi4503 is clearly due to microtubule collapse and vascular shut-down, the formation of toxic free radicals likely contributes to its enhanced potency...
  35. ncbi request reprint Simultaneous targeting of VEGF message and VEGF receptor signaling as a therapeutic anticancer approach
    Wenyin Shi
    Department of Radiation Oncology, Shands Cancer Center, University of Florida, Gainesville, FL 32610, USA
    Anticancer Res 24:213-8. 2004
    ..Vascular endothelial growth factor (VEGF) is one of the most important factors involved in tumor angiogenesis...
  36. doi request reprint BMS-777607, a small-molecule met kinase inhibitor, suppresses hepatocyte growth factor-stimulated prostate cancer metastatic phenotype in vitro
    Yao Dai
    Department of Radiation Oncology, University of Florida, Cancer Genetic Research Complex, Room 485E, Gainesville, Florida 32610, USA
    Mol Cancer Ther 9:1554-61. 2010
    ....
  37. ncbi request reprint Effect of the second-generation vascular disrupting agent OXi4503 on tumor vascularity
    Howard W Salmon
    Department of Radiation Oncology, Shands Cancer Center, University of Florida, Gainesville, Florida 32610, USA
    Clin Cancer Res 12:4090-4. 2006
    ..One such agent is the combretastatin A4 disodium phosphate (CA4P) analogue OXi4503 (CA1P)...
  38. ncbi request reprint Augmented antitumor effects of radiation therapy by 4-1BB antibody (BMS-469492) treatment
    Wenyin Shi
    Department of Radiation Oncology, Shands Cancer Center, University of Florida, Gainesville, FL 32610, USA
    Anticancer Res 26:3445-53. 2006
    ..The immune response induced by 4-1BB monoclonal antibodies (mAbs) has been shown to have a marked augmentation of tumor-selective cytolytic T cell activity...
  39. pmc Monitoring the treatment efficacy of the vascular disrupting agent CA4P
    Beth A Salmon
    Department of Pharmacology and Therapeutics, University of Florida, Gainesville, FL, USA
    Eur J Cancer 43:1622-9. 2007
    ..However, tumour perfusion correlated (r=0.89, p<0.00001) with CA4P treatment efficacy as measured by necrotic fraction, suggesting that DCE-MRI may have utility in a clinical setting...
  40. ncbi request reprint Radiotherapy alone or combined with carbogen breathing for squamous cell carcinoma of the head and neck: a prospective, randomized trial
    William M Mendenhall
    Department of Radiation Oncology, University of Florida College of Medicine, Gainesville, Florida 32610, USA
    Cancer 104:332-7. 2005
    ..The current study was performed to investigate the efficacy of carbogen (95% oxygen [O(2)] and 5% carbon dioxide [CO(2)]) breathing during definitive radiotherapy (RT) to enhance local control...
  41. ncbi request reprint Impact of the Src inhibitor saracatinib on the metastatic phenotype of a fibrosarcoma (KHT) tumor model
    Meiyu Dong
    Department of Radiation Oncology, 2033 Mowry Rd Rm 485E, Gainesville, FL 32610, USA
    Anticancer Res 30:4405-13. 2010
    ..The aim of the present studies was to examine the impact of an Src inhibitor (saracatinib) on a highly metastatic murine sarcoma cell line (KHT)...
  42. doi request reprint Development of an intramuscular xenograft model of canine osteosarcoma in mice for evaluation of the effects of radiation therapy
    Alastair R Coomer
    Departments of Small Animal Clinical Sciences College of Medicine, University of Florida, Gainesville, FL 32610, USA
    Am J Vet Res 70:127-33. 2009
    ..To develop an IM xenograft model of canine osteosarcoma in mice for the purpose of evaluating effects of radiation therapy on tumors...
  43. ncbi request reprint Comparison of the EF-1 alpha and the CMV promoter for engineering stable tumor cell lines using recombinant adeno-associated virus
    Christian Teschendorf
    Department of Molecular Genetics and Microbiology, College of Medicine, University of Florida, P O Box 100266, JHMHSC, Gainesville, FL 32610, USA
    Anticancer Res 22:3325-30. 2002
    ..Silencing of the viral CMV immediate early enhancer promoter can be a problem in certain cell types when engineering stable cell lines...
  44. ncbi request reprint Postoperative radiation therapy for squamous cell carcinoma of the head and neck
    William M Mendenhall
    Departments of Radiation Oncology, University of Florida, College of Medicine, Gainesville, FL 32610 0385, USA
    Am J Otolaryngol 24:41-50. 2003
    ..To discuss the role of postoperative radiation therapy (RT) for patients with squamous cell carcinoma of the head and neck...
  45. ncbi request reprint Recombinant adeno-associated and adenoviral vectors for the transduction of pancreatic and colon carcinoma
    Christian Teschendorf
    Department of Molecular Genetics and Microbiology, College of Medicine, University of Florida, Gainesville, FL 32610, USA
    Anticancer Res 26:311-7. 2006
    ..Materials and Methods: The transduction efficiency of rAAV2 in pancreatic and colon cancer was compared to that of recombinant adenovirus (rAd) in vitro and in vivo using green fluorescent protein (GFP)...
  46. doi request reprint Expression of pluripotent stem cell reprogramming factors by prostate tumor initiating cells
    Kyung Mi Bae
    Department of Urology Prostate Disease Center, College of Medicine and Flow Cytometry Core Facility, University of Florida, Gainesville, Florida 32610, USA
    J Urol 183:2045-53. 2010
    ..We identified a discrete population of stem cell-like tumor cells expressing 5 essential transcription factors required to reprogram pluripotency in prostate tumor cell lines and primary prostate cancer tissue...
  47. ncbi request reprint Targeting the tumor blood vessel network to enhance the efficacy of radiation therapy
    Dietmar W Siemann
    Department of Radiation Oncology, University of Florida, Gainesville, FL 32610, USA
    Semin Radiat Oncol 13:53-61. 2003
    ..The application of such strategies as adjuvants to conventional radiation treatments offers unique opportunities to develop more effective cancer therapies...
  48. ncbi request reprint Oxidative stress regulates expression of VEGFR1 in myeloid cells: link to tumor-induced immune suppression in renal cell carcinoma
    Sergei Kusmartsev
    Department of Urology, College of Medicine, University of Florida, Gainesville, FL 32610, USA
    J Immunol 181:346-53. 2008
    ..Restoration of immunocompetence in metastatic RCC patients by pharmacological elimination of VEGFR1+ cells may have a significant impact on the therapeutic efficacy of cancer vaccines or other immune-based therapies...
  49. ncbi request reprint Utility of 19F MRS detection of the hypoxic cell marker EF5 to assess cellular hypoxia in solid tumors
    Howard W Salmon
    Department of Nuclear and Radiological Engineering, University of Florida, Gainesville, FL 32610, USA
    Radiother Oncol 73:359-66. 2004
    ..The present studies were undertaken to determine whether 19F MRS could be used to quantify the binding of the pentafluorinated derivative of etanidazole (EF5) in hypoxic cells of solid tumors...
  50. doi request reprint Intrinsic radiosensitivity and repair of sublethal radiation-induced damage in canine osteosarcoma cell lines
    Courtney L Fitzpatrick
    Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, Gainesville, FL 32610, USA
    Am J Vet Res 69:1197-202. 2008
    ..To characterize the radiosensitivity and capacity for sublethal damage repair (SLDR) of radiation-induced injury in 4 canine osteosarcoma cell lines...
  51. ncbi request reprint The 93rd Annual Meeting of the American Association for Cancer Research. 6-10 April 2002, San Francisco, California, USA
    J Martin Brown
    Stanford University, Stanford, California, USA
    Expert Opin Pharmacother 3:629-32. 2002
    ..There was a mind-boggling array of choices for those interested in cancer research. This meeting was the largest ever convened on a single disease. We will endeavour to provide some of the highlights of this exciting meeting...
  52. pmc Bone marrow stem and progenitor cell contribution to neovasculogenesis is dependent on model system with SDF-1 as a permissive trigger
    Gerard J Madlambayan
    Program in Stem Cell Biology and Regenerative Medicine, University of Florida, Gainesville, Florida, USA
    Blood 114:4310-9. 2009
    ..The varied BM contribution seen in different model systems is suggestive of redundant mechanisms governing postnatal neovasculogenesis and provides an explanation for contradictory results observed in the field...
  53. ncbi request reprint Education and training for radiation scientists: radiation research program and American Society of Therapeutic Radiology and Oncology Workshop, Bethesda, Maryland, May 12-14, 2003
    C Norman Coleman
    Radiation Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland, USA
    Radiat Res 160:729-37. 2003
    ..5) Educate other scientists and the general public on the quantitative, basic, molecular, translational and applied aspects of radiation sciences...

Research Grants24

  1. Combining Anti Angiogenesis Strategies and Radiotherapy
    Dietmar Siemann; Fiscal Year: 2005
    ..We believe that these studies will provide essential insights into the therapeutic utility of employing antiangiogenic treatment strategies as adjuvants to radiotherapy. ..
  2. ENHANCING RADIATION THERAPY: VASCULAR TARGETING AGENTS
    Dietmar Siemann; Fiscal Year: 2007
    ....
  3. Combining Anti-Angiogenesis Strategies and Radiotherapy
    Dietmar W Siemann; Fiscal Year: 2010
    ..Experiments are designed to investigate the mechanisms underlying the interaction between such therapies and to develop approaches that would maximize the anti-tumor efficacy of such combined treatments. ..
  4. RADIATION AND DRUG EFFECTS ON TUMOR CELL SUBPOPULATIONS
    Dietmar Siemann; Fiscal Year: 2001
    ..Ultimately we hope that these approaches can be reliably developed to an extent where the use of human tumor biopsy material may lead to radiotherapy treatments more tailored to the individual patient. ..
  5. ENHANCING RADIATION THERAPY: VASCULAR TARGETING AGENTS
    Dietmar W Siemann; Fiscal Year: 2010
    ..Experiments are designed to investigate how to deliver such therapies for maximum antitumor efficacy as well as determining the potential of developing predictive indicators of their treatment response. ..